Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Purple Biotech (PPBT) Assets (2016 - 2025)

Purple Biotech has reported Assets over the past 7 years, most recently at $54.6 million for Q4 2022.

  • Quarterly Assets fell 22.19% to $54.6 million in Q4 2022 from the year-ago period, while the trailing twelve-month figure was $54.6 million through Dec 2022, down 22.19% year-over-year, with the annual reading at $54.6 million for FY2022, 22.19% down from the prior year.
  • Assets was $54.6 million for Q4 2022 at Purple Biotech, down from $58.5 million in the prior quarter.
  • Over five years, Assets peaked at $85.8 million in Q2 2020 and troughed at $14.7 million in Q4 2019.
  • The 5-year median for Assets is $64.0 million (2022), against an average of $55.6 million.
  • Year-over-year, Assets soared 469.39% in 2020 and then dropped 22.19% in 2022.
  • A 5-year view of Assets shows it stood at $14.7 million in 2018, then decreased by 0.03% to $14.7 million in 2019, then soared by 469.39% to $83.8 million in 2020, then dropped by 16.23% to $70.2 million in 2021, then dropped by 22.19% to $54.6 million in 2022.
  • Per Business Quant, the three most recent readings for PPBT's Assets are $54.6 million (Q4 2022), $58.5 million (Q3 2022), and $61.7 million (Q2 2022).